Asset Details
Do you wish to reserve the book?
Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis
Do you wish to request the book?
Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Natalizumab restores evoked potential abnormalities in patients with relapsing–remitting multiple sclerosis
2011
Overview
Background and Objective: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing–remitting multiple sclerosis patients.
Methods: EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale.
Results: Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment (p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level.
Conclusions: Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems.
Publisher
SAGE Publications,Sage Publications,Sage Publications Ltd
Subject
/ Adult
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Biological and medical sciences
/ Evoked Potentials - drug effects
/ Evoked Potentials, Motor - drug effects
/ Evoked Potentials, Somatosensory - drug effects
/ Evoked Potentials, Visual - drug effects
/ Female
/ Germany
/ Humans
/ Immunologic Factors - therapeutic use
/ Male
/ Multiple Sclerosis, Relapsing-Remitting - diagnosis
/ Multiple Sclerosis, Relapsing-Remitting - drug therapy
/ Multiple Sclerosis, Relapsing-Remitting - physiopathology
/ Tibial Nerve - physiopathology
